

MAY 1 9 2000

K 001043

510(K) SUMMARY

1. SUBMITTER

AGENT

KAWASUMI LABORATORIES, INC.  
3-28-15 MINAMI-OHI  
SHINAGAWA-KU, TOKYO 140 JAPAN  
PHONE: 81-3-376-1151  
FAX: 81-3-376-3235  
CONTACT: MR. S. SUWA

KAWASUMI LABORATORIES AMERICA, INC.  
5909 C HAMPTON OAKS PARKWAY  
TAMPA, FL 33610  
PHONE: 813-630-5554  
FAX: 813-630-5033  
CONTACT: MR. JACK PAVLO

2. NAME OF DEVICE: KAWASUMI LABORATORIES BLOOD DRAWING KIT

COMMON NAME: BLOOD LETTING KIT, PHLEBOTOMY KIT OR SET

3. PREDICATE DEVICE: BAXTER HEALTHCARE FENWAL DIV., EMPTY SINGLE BLOOD-PACK UNIT

4. DESCRIPTION OF THE DEVICE: A STERILE, SINGLE USE DEVICE FOR WITHDRAWING BLOOD..

BASIC CONCEPT: A CONDUIT USED FOR WITHDRAWING BLOOD FROM THE PATIENT'S VEIN TO A BLOOD BAG RESERVOIR

SIGNIFICANT PERFORMANCE CHARACTERISTICS: THERE ARE NO SIGNIFICANT PERFORMANCE CHARACTERISTICS OF THIS DEVICE COMPARED TO SUBSTANTIALLY EQUIVALENT DEVICES MARKETING FOR SALE IN INTERSTATE COMMERCE. THE DEVICE IS USED TO REMOVE BLOOD FROM A PATIENT INTO A BLOOD BAG RESERVOIR.

5. INTENDED USE: THE BLOOD DRAWING KIT IS USED AS A THERAPEUTIC DEVICE TO REMOVE BLOOD FROM A PATIENT INTO A BLOOD BAG RESERVOIR.

6. TECHNOLOGICAL CHARACTERISTICS: THERE ARE NO TECHNOLOGICAL CHARACTERISTICS OF THIS DEVICE TO THE SUBSTANTIALLY EQUIVALENT DEVICE FROM BAXTER HEALTHCARE, FENWAL DIV., BEING MARKETING FOR SALE IN INTERSTATE COMMERCE.

7. PERFORMANCE DATA: KAWASUMI LABORATORIES HAS CONDUCTED BIOCOMPATIBILITY TESTS ON THE BODY FLUID CONTACTING MATERIAL PORTIONS OF THE DEVICE AND KL BELIEVES THE BIOCOMPATIBILITY DATA SHOW THE DEVICE IS SUITABLE FOR ITS INTENDED USE.

8. CONCLUSIONS: THE DEVICE MEETS ALL BIOCOMPATIBILITY AND PYROGENICITY TEST REQUIREMENTS. THEREFORE, IT IS AS SAFE AS THE PREDICATE DEVICE AND PERFORMS AS WELL AS THE PREDICATE DEVICE.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAY 19 2000

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. Jack Pavlo  
Kawasumi Laboratories America, Limited  
5905 C Hampton Oaks Parkway  
Tampa, Florida 33610

Re: K001043  
Trade Name: Kawasumi Laboratories Blood Drawing Kit  
Regulatory Class: II  
Product Code: KSB and LHI  
Dated: March 30, 2000  
Received: March 31, 2000

Dear Mr. Pavlo:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Pavlo

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

  
f Timothy A. Ulatowski  
Director  
Division of Dental, Infection Control,  
and General Hospital Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

K001043

INDICATIONS FOR USE

DEVICE NAME: KAWASUMI LABORATORIES BLOOD DRAWING KIT

INDICATIONS FOR USE: A THERAPEUTIC DEVICE USED FOR BLOOD REMOVAL FROM A  
PATIENT TO A BLOOD BAG RESERVOIR TO AID IN THE TREATMENT  
OF A DISEASE OR OTHER CONDITION. THIS DEVICE IS NOT  
INTENDED FOR BLOOD TRANSFUSION.

Rafaela Conceição

(Division Sign-Off)

Division of Dental, Infection Control,  
and General Hospital Devices

510(k) Number K001043